These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 28705532)

  • 21. Combination therapy with galantamine and memantine improves behavioral and psychological symptoms of dementia (BPSD) in patients with early-onset Alzheimer's disease.
    Hamuro A
    Aust N Z J Psychiatry; 2013 Jun; 47(6):583. PubMed ID: 23093052
    [No Abstract]   [Full Text] [Related]  

  • 22. Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population.
    Prasher VP
    Int J Geriatr Psychiatry; 2004 Jun; 19(6):509-15. PubMed ID: 15211527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.
    Di Santo SG; Prinelli F; Adorni F; Caltagirone C; Musicco M
    J Alzheimers Dis; 2013; 35(2):349-61. PubMed ID: 23411693
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Alzheimer drugs for mild cognitive impairment].
    Fellgiebel A
    Neuropsychiatr; 2007; 21(3):230-3. PubMed ID: 17915184
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dementia.
    Warner J; Butler R; Arya P
    Clin Evid; 2004 Dec; (12):1361-90. PubMed ID: 15865724
    [No Abstract]   [Full Text] [Related]  

  • 26. The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer's disease.
    Rockwood K; Fay S; Gorman M
    Int J Geriatr Psychiatry; 2010 Feb; 25(2):191-201. PubMed ID: 19548273
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacotherapy for Vascular Cognitive Impairment.
    Farooq MU; Min J; Goshgarian C; Gorelick PB
    CNS Drugs; 2017 Sep; 31(9):759-776. PubMed ID: 28786085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of CDP-choline and the combination of CDP-choline and galantamine differ in an animal model of schizophrenia: development of a selective alpha7 nicotinic acetylcholine receptor agonist strategy.
    Deutsch SI; Rosse RB; Schwartz BL; Schooler NR; Gaskins BL; Long KD; Mastropaolo J
    Eur Neuropsychopharmacol; 2008 Feb; 18(2):147-51. PubMed ID: 17656074
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dementia.
    Warner J; Butler R; Wuntakal B
    Clin Evid; 2005 Dec; (14):1198-220. PubMed ID: 16620452
    [No Abstract]   [Full Text] [Related]  

  • 30. The safety and tolerability of galantamine in patients with epilepsy and memory difficulties.
    Griffith HR; Martin R; Andrews S; LeBron Paige A; Ware J; Faught E; Welty T
    Epilepsy Behav; 2008 Aug; 13(2):376-80. PubMed ID: 18556248
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of the combination of memantine plus vitamin D on cognition in patients with Alzheimer disease: a pre-post pilot study.
    Annweiler C; Herrmann FR; Fantino B; Brugg B; Beauchet O
    Cogn Behav Neurol; 2012 Sep; 25(3):121-7. PubMed ID: 22960436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacologic treatment options in Alzheimer's disease: optimizing disease management.
    Aisen PS
    J Am Acad Nurse Pract; 2005 Mar; Suppl():5-7. PubMed ID: 16033023
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effective pharmacological management of Alzheimer's disease.
    Atri A
    Am J Manag Care; 2011 Nov; 17 Suppl 13():S346-55. PubMed ID: 22214392
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study.
    Mega MS; Dinov ID; Porter V; Chow G; Reback E; Davoodi P; O'Connor SM; Carter MF; Amezcua H; Cummings JL
    Arch Neurol; 2005 May; 62(5):721-8. PubMed ID: 15883258
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic effect of combined treatment with risperidone and galantamine on phencyclidine-induced impairment of latent visuospatial learning and memory: Role of nAChR activation-dependent increase of dopamine D1 receptor-mediated neurotransmission.
    Wang D; Noda Y; Zhou Y; Nitta A; Furukawa H; Nabeshima T
    Neuropharmacology; 2007 Sep; 53(3):379-89. PubMed ID: 17632185
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of combine treatment of memantine and donepezil on Alzheimer's disease patients and its relationship with cerebral blood flow in the prefrontal area.
    Araki T; Wake R; Miyaoka T; Kawakami K; Nagahama M; Furuya M; Limoa E; Liaury K; Hashioka S; Murotani K; Horiguchi J
    Int J Geriatr Psychiatry; 2014 Sep; 29(9):881-9. PubMed ID: 24436135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prescribing trends in cognition enhancing drugs in Australia.
    Hollingworth SA; Byrne GJ
    Int Psychogeriatr; 2011 Mar; 23(2):238-45. PubMed ID: 20670461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Galantamine improves gait performance in patients with Alzheimer's disease.
    Assal F; Allali G; Kressig RW; Herrmann FR; Beauchet O
    J Am Geriatr Soc; 2008 May; 56(5):946-7. PubMed ID: 18454755
    [No Abstract]   [Full Text] [Related]  

  • 39. Psychopharmacologic intervention after hemorrhagic basal ganglia damage.
    Al Owesie RM; Morton CS
    J Neurol Sci; 2012 Nov; 322(1-2):77-8. PubMed ID: 22795553
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial.
    Scarpini E; Bruno G; Zappalà G; Adami M; Richarz U; Gaudig M; Jacobs A; Schäuble B
    J Alzheimers Dis; 2011; 26(2):211-20. PubMed ID: 21606568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.